MedTrace Logo

CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

NCT06304857 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-12-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.

Conditions

Interventions

DRUG

Dapagliflozin

10 mg tablet q.d

DRUG

Placebo

tablet matching dapagliflozin 10 mg q.d

Sponsors & Collaborators

  • 4th Military Clinical Hospital with Polyclinic, Poland

    lead OTHER

Principal Investigators

  • Waldemar Banasiak, PhD, MD · 4th Military Clinical Hospital with Polyclinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06304857 on ClinicalTrials.gov